Sentences with phrase «more aggressive prostate cancer»

Men with a variant may develop earlier and more aggressive prostate cancer.

«These results suggest low levels of testosterone are associated with more aggressive prostate cancer.

Depressed men with localized prostate cancer were more likely to be diagnosed with more aggressive prostate cancer, received less effective treatments and survived for shorter times than prostate cancer patients who were not depressed, a UCLA study has found.

Eating a diet higher in saturated fat, a type of fat found commonly in foods such as fatty beef and cheese, was linked to more aggressive prostate cancer, a study by University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators has found.

«Researchers find protein that may signal more aggressive prostate cancers.»

Not exact matches

«Markers for prostate cancer death can identify men in need of more aggressive treatment.»

«This study demonstrates that targeted fusion - guided biopsy could significantly enhance our ability to identify patients with high - risk prostate cancers that need more aggressive treatment,» says lead author Mohummad Minhaj Siddiqui, MD, assistant professor of surgery at the University of Maryland School of Medicine and director of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

«Why prostate cancer is more aggressive in obese patients.»

Even more troubling, her study found a link between high blood levels of lycopene's chemical cousin, beta - carotene, and an increased risk of aggressive prostate cancer — not enough to justify avoiding carrots and other food sources of beta - carotene but an ominous sign that not all food - derived compounds are necessarily benign when taken at higher doses.

«A more complete Mediterranean diet may protect against aggressive prostate cancer: New study in The Journal of Urology ® finds that a high intake of fruits, vegetables, and whole grains might not be enough.»

«This combination test is not designed to say definitively at diagnosis whether a man has aggressive prostate cancer, but it can provide a more accurate estimate of the likelihood of having cancer and the likelihood of that cancer being aggressive,» Tomlins says.

Mi - Prostate Score, or MiPS, was significantly more accurate than PSA alone for predicting cancer as well as predicting aggressive prostate cancer that is likely to grow and spread Prostate Score, or MiPS, was significantly more accurate than PSA alone for predicting cancer as well as predicting aggressive prostate cancer that is likely to grow and spread prostate cancer that is likely to grow and spread quickly.

By age 80, more than 50 percent of men will develop prostate cancer but not all will have the aggressive, deadly form of the disease.

UCLA researchers found that conventional «blind» biopsy failed to reveal the true extent of presumed low - risk prostate cancers, and that when targeted biopsy was used, more than a third of these men had more aggressive cancers than they thought.

«For men with prostate cancer, emotional distress may lead to more aggressive treatment.»

Denmeade says the combination of drugs that block testosterone production and receptors, called androgen deprivation therapy, may make prostate cancer more aggressive over time by enabling prostate cancer cells to subvert attempts to block testosterone receptors.

«Emotional distress may motivate men with low - risk prostate cancer to choose more aggressive treatment, such as choosing surgery over active surveillance,» said UB's Heather Orom, the lead author on the study, published in the February issue of the Journal of Urology.

The authors stressed that the long - term reduction in aggressive disease was observed only in men after more than a year of testosterone use, and the risk of prostate cancer did not differ between gels and other types of preparations.

The old idea that cancer is less aggressive in the elderly is not entirely without merit: breast and prostate cancers tend to grow more slowly in older patients.

«Metastatic prostate cancer cases skyrocket: More lax screening rather than more aggressive disease?.&raMore lax screening rather than more aggressive disease?.&ramore aggressive disease?.»

Dr Hayley Luxton, lead researcher from the Molecular Diagnostics and Therapeutics Laboratory at University College London, said: «Using antibodies mounted with a toxic payload, we can exploit the fact that aggressive prostate cancer cells have more NAALADL2.

Similarly men with these gene variants were three times more likely to be diagnosed with aggressive prostate cancer (Gleason 8 or more).

The researchers are now further investigating the possibility of using this approach on other cancers, including prostate cancer, where it could be used to distinguish more aggressive tumors from those that grow much more slowly, Bhatia says.

«What was most surprising was that patients who underwent aggressive treatment for their prostate cancer were more likely to receive routine lab testing and visits with their doctor than those not receiving aggressive treatment.

Furthermore, they found that D4A is more effective than abiraterone at killing aggressive prostate cancer cells, suggesting that some patients may benefit from direct treatment with D4A.

«Researcher discovers metabolite of prostate cancer drug more effective at treating aggressive tumors.»

After following 154 men with low - risk prostate cancer for 38 months, the investigators found that low levels of free testosterone were significantly linked with an increased risk of developing more aggressive disease.

Like pervasive hypertension, some cancers, such as prostate and breast, tend to occur earlier and be more aggressive in blacks than whites, said Dr. Edward J. Kruse, chief of surgical oncology at MCG and the Georgia Cancer Center.

Men with BRCA1 / 2 mutations who develop prostate cancer tend to develop these cancers at an earlier age than average and may develop more aggressive forms of the disease.

A new urine - based test improved prostate cancer detection — including detecting more aggressive forms of prostate cancer — compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.

Men with these mutations are more likely than non-carriers to contract aggressive, lethal prostate cancer, to be diagnosed at a more advanced stage and to ultimately die of the disease, researchers say.

Mutations in the beta - catenin gene, or flaws in the factors that degrade it, have long been linked to more aggressive disease in various tumor types, including colon, lung and prostate cancer, and melanoma.

Carriers of germline mutations in BRCA2 have at least five times greater risk of prostate cancer and frequently develop a more aggressive form of the disease.

One of the SNPs is located on the X chromosome and the other SNP is located on chromosome 2p15 and is associated with a more aggressive form of prostate cancer.

Newly published research from Fred Hutch shows black men may be at heightened risk not only of developing prostate cancer but also of having a more aggressive form at a younger age.

A study was done in 2013 which proved that patients who had poor sleeping habits were much more likely to develop an aggressive form of prostate cancer.

While men with the more aggressive form of the cancer make up about 5 % of the 180,000 to 200,000 cases of prostate cancer in the U.S. each year, and only 12 % will have these mutations, that population is still at considerably higher risk of developing advanced disease.

In a report published in the New England Journal of Medicine, scientists say that a panel of 20 genes can distinguish the more common localized prostate cancer that grows slowly and rarely spreads from the more aggressive type that can spread quickly.

The findings also hint that in coming years, it may be possible to use the panel not just among men with advanced disease but to distinguish between men who develop the slower growing type of prostate cancer from the more aggressive type.

The task force also calls for more research in this area, including ongoing studies looking at the potential for MRI and genetic testing to better detect aggressive prostate cancers, Krist added.

In the Prostate Cancer Prevention Trial, a study involving more than 18,000 men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebProstate Cancer Prevention Trial, a study involving more than 18,000 men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo Cancer Prevention Trial, a study involving more than 18,000 men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancers than the placebo group.

This resulted in a higher absolute number of aggressive prostate cancers in the dutasteride group than in the placebo group — even though the placebo group had a higher rate of prostate cancer.141 Thus, as we have seen elsewhere, e.g., rofecoxib (Vioxx ®), celecoxib (Celebrex ®), balance in biological processes is more beneficial than absolute interruption.)

In the Prostate Cancer Prevention Trial, a study involving more than eighteen thousand men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebProstate Cancer Prevention Trial, a study involving more than eighteen thousand men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo Cancer Prevention Trial, a study involving more than eighteen thousand men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancers than the placebo group.

This resulted in a higher absolute number of aggressive prostate cancers in the dutasteride group than in the placebo group — even though the placebo group had a higher rate of prostate cancer.145 (See above «Mechanisms through which 5α - reductase inhibitors promote prostate cancer»)(Neal, please make this a link to this section above) Thus, as we have seen elsewhere, e.g., rofecoxib (Vioxx ®), celecoxib (Celebrex ®), balance in biological processes is more beneficial than absolute interruption.)

Prostate cancer in dogs is much more aggressive in humans and spreads rapidly.